Metsera eyes $289M IPO to fund phase 3 weight loss trial https://www.fiercebiotech.com/biotech/metsera-eyes-289m-ipo-fund-phase-3-weight-loss-trial
Fierce BiotechMetsera eyes $289M IPO to fund phase 3 weight loss trialMetsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on …January 27, 2025 4.4K 7
